ImpediMed

ImpediMed Short-term Debt

The Short-Term Debt of ImpediMed (IPD.AX) as of Nov 12, 2026 is 296,000.00 AUD. In the previous year, Short-Term Debt was 266,000.00 AUD — a change of 11.28% (higher).

Short-term Debt

296,000.00AUD

YoY

11.28%

Last updated:

Short-Term Debt of ImpediMed is 2026 296,000.00 AUD. Short-Term Debt of ImpediMed was 2025 266,000.00 AUD. It decreases by 11.28% higher compared to the previous year.

The ImpediMed Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2019
520,000.00 AUD
Jan 1, 2020
364,000.00 AUD
Jan 1, 2021
315,000.00 AUD
Jan 1, 2022
170,000.00 AUD
Jan 1, 2023
300,000.00 AUD
Jan 1, 2024
333,000.00 AUD
Jan 1, 2025
266,000.00 AUD
Jan 1, 2026
296,000.00 AUD
The ImpediMed Short-term Debt history
YEARShort-term DebtYoY
296,000.00AUD+11.28%
266,000.00AUD-20.12%
333,000.00AUD+11.00%
300,000.00AUD+76.47%
170,000.00AUD-46.03%
315,000.00AUD-13.46%
364,000.00AUD-30.00%
520,000.00AUD+126.09%
230,000.00AUD+296.55%
58,000.00AUD-20.55%
73,000.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Short-Term Debt of ImpediMed is 296,000.00 AUD in 2026.

Short-Term Debt of ImpediMed changed from 266,000.00 AUD to 296,000.00 AUD, representing a 11.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's ImpediMed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ImpediMed

All Key Metrics — ImpediMed